IMpower110 — Atezolizumab Versus Chemotherapy in Untreated PD-L1-Selected Advanced NSCLC (IMpower110)

Phase 3 · 2020 · Non-Small Cell Lung Cancer

Design

Randomized, open-label trial of first-line atezolizumab monotherapy vs platinum-based chemotherapy.

Population

Untreated stage IV non-squamous or squamous NSCLC without EGFR/ALK alterations and with PD-L1 expression.

Primary Endpoint

overall survival (OS) by PD-L1 subgroup

Key Result

In high PD-L1 expression (TC3/IC3), median OS 20.2 vs 13.1 mo (HR 0.59, P=0.01).

Guideline Impact

FDA-approved 2020; NCCN-listed first-line atezolizumab for high-PD-L1 NSCLC without driver mutations